Literature DB >> 6335090

BT-Paba test in the diagnosis of pancreatic exocrine insufficiency in cystic fibrosis: urinary and serum determinations compared.

S Bellentani, A Grisendi, M Rinaldi, P Bertolani, G Costa, M Agostini, G Mastella, F Balli, F Manenti.   

Abstract

Urinary recovery and serum determination of Paba were carried out in 48 control children (C) and 53 paediatric patients with cystic fibrosis (CF) divided into three classes by age. Ninety and 120 min after the ingestion of 15 mg/kg of BT-Paba and of a standard meal, serum Paba was determined. In the same subjects the percentage Paba recovery was measured in the urine collected during an 8 h period after the same administration of BT-Paba. Correlation between urinary and serum Paba values was higher in the older children in respect to the 0-2-year-old infants. A urinary Paba test was less sensitive and specific than a serum Paba test in the evaluation of exocrine pancreatic function. The best discrimination between C and children with CF, using the maximal value of serum Paba at 90 or 120 min (peak), was obtained in the younger infants (0-2 years old). BT-Paba test with serum Paba peak determination is recommended as a substitute for the classical urinary Paba test in the evaluation of exocrine pancreatic function in paediatric patients, especially in the younger infants.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6335090     DOI: 10.1007/bf00445804

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  7 in total

1.  Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid.

Authors:  S Nousia-Arvanitakis; C Arvanitakis; N Desai; N J Greenberger
Journal:  J Pediatr       Date:  1978-05       Impact factor: 4.406

2.  PABA screening test for exocrine pancreatic function in infants and children.

Authors:  M Sacher; A Kobsa; D H Shmerling
Journal:  Arch Dis Child       Date:  1978-08       Impact factor: 3.791

3.  [Indirect assessment of exocrine pancreatic function by oral administration of a synthetic peptide, N-benzoyl-L-tyrosyl-para-amino-benzoic-acid (PABA test) (author's transl)].

Authors:  A Ribet; J Frexinos; J Escourrou; N Vaysse; Y Arany; M Varignon
Journal:  Gastroenterol Clin Biol       Date:  1979-03

4.  BT-PABA test with plasma PABA measurements: evaluation of sensitivity and specificity.

Authors:  J C Delchier; J C Soule
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

5.  Diagnosis of pancreatic disease by a synthetic peptide. A new test of exocrine pancreatic function.

Authors:  C Arvanitakis; N J Greenberger
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

6.  [The PABA test in chronic pancreatitis: value of plasma para-amino benzoic acid determinations (author's transl)].

Authors:  J P Breau; C Théodore; T Evstigneeff; J Sancho; J Vitaux; E Delacoux; J A Paolaggi
Journal:  Nouv Presse Med       Date:  1981-12-05

7.  Determination of protease-cleaved p-aminobenzoic acid (PABA) in serum after oral administration of N-benzoyl-L-tyrosyl-p-aminobenzoic acid (PABA-peptide) in children.

Authors:  G Dockter; I Nacu; E Kohlberger
Journal:  Eur J Pediatr       Date:  1981-02       Impact factor: 3.183

  7 in total
  3 in total

1.  Pancreatic function testing: serum PABA measurement is a reliable and accurate measurement of exocrine function.

Authors:  A R Tanner; D P Robinson
Journal:  Gut       Date:  1988-12       Impact factor: 23.059

2.  The development of the chymotryptic activity during postnatal life using the bentiromide test.

Authors:  Y Bujanover; A Harel; R Geter; H Blau; J Yahav; Z Spirer
Journal:  Int J Pancreatol       Date:  1988 Jan-Feb

3.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.